X0306 4 2020-02-13 0 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001721442 Sabag Mark C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 5 BASEL STREET PETACH TIKVA L3 4951033 ISRAEL 0 1 0 0 See "Remarks" below Ordinary Shares 2020-02-13 4 S 0 72130.5421 13.0286 D 0 D Ordinary Shares 2020-02-14 4 M 0 19040 A 19040 D Ordinary Shares 2020-02-14 4 M 0 5710 A 24750 D Restricted Share Units 2020-02-14 4 M 0 5710 0.00 D Ordinary Shares 5710 5712 D Restricted Share Units 2020-02-14 4 M 0 19040 0.00 D Ordinary Shares 19040 0 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.8525 to $13.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on February 14, 2017, with 5,710 vesting on each of February 14, 2019 and February 14, 2020 and 5,712 vesting on February 14, 2021. Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020. EVP, Chief Human Resources Officer and Corporate Brand and Communications /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag 2020-02-18